Trial reportCancer medicine2021
Combination of body mass index and albumin predicts the survival in metastatic castration-resistant prostate cancer patients treated with abiraterone: A post hoc analysis of two randomized trials.
Trial report in Cancer medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.
- [Comorbidities affecting abiraterone treatment in patients with metastatic castration-resistant prostate cancer: a meta- analysis].Magyar onkologia · 2026Pooled it
- Association between overweight and obesity determined by body mass index and overall survival in patients with metastatic prostate cancer: a meta-analysis.International journal of obesity (2005) · 2025Pooled it
- Combination of body mass index and albumin predicts the survival in metastatic castration-resistant prostate cancer patients treated with abiraterone: A post hoc analysis of two randomized trials.Cancer medicine · 2021Trial
- A Gene Feature Based on Histone Modifications Can Predict the Prognosis of Prostate Cancer.Biomedicines · 2026Article
- Metabolic profile and skeletal muscle as predictors of survival in testicular germ cell tumors.The oncologist · 2026Article
- Paradoxical Effect of Obesity on Survival Outcomes in Prostate Cancer Patients Receiving Enzalutamide and Abiraterone.Medicina (Kaunas, Lithuania) · 2026Article
- Modified body mass index as a novel prognostic indicator of in-hospital mortality after off-pump coronary artery bypass grafting: A nationwide multicenter cohort study.International journal of cardiology. Heart & vasculature · 2025Article
- Prognostic factors for overall survival in castration-resistant metastatic prostate cancer treated with docetaxel (MeProCSS): results from a German real-world cohort.International urology and nephrology · 2025Article
- The diagnostic value of inflammatory markers in bone metastasis of prostate cancer at initial prostate biopsy.Frontiers in oncology · 2025Article
- Prognostic value of three clinical nutrition scoring system (NRI, PNI, and CONUT) in elderly patients with prostate cancer.Frontiers in nutrition · 2024Article
- Effect of Moderate Malnutrition on the Pharmacokinetics of Etoposide and Vincristine in Freshly Weaned Rats.European journal of drug metabolism and pharmacokinetics · 2023Article
- Dietary and Serum Antioxidants Associated with Prostate-Specific Antigen for Middle-Aged and Older Men.Nutrients · 2023Article
- Systemic inflammatory biomarkers as predictive and prognostic factors in men with metastatic castration-refractory prostate cancer treated with docetaxel therapy: a comprehensive analysis in a German real-world cohort.Journal of cancer research and clinical oncology · 2023Article
- Real-life data of abiraterone acetate and enzalutamide treatment in post-chemotherapy metastatic castration-resistant prostate cancer in Poland.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundLow body mass index (BMI) and low serum albumin levels are suggested indicators of malnutrition and are associated with poor outcomes in cancer patients. Decreasing androgen can alter lipid metabolism, so the prognostic value of BMI may change in metastatic castration-resistant prostate cancer (mCRPC) patients receiving abiraterone. We aimed to delineate the prognostic value of BMI, serum albumin, and BMI and serum albumin (ALB) combined. MATERIALS AND
methodsA post hoc analysis was performed on data from two randomized clinical trials evaluating the efficacy of abiraterone in chemotherapy-pretreated and -naïve mCRPC patients. Survival analysis was conducted using Kaplan-Meier and Cox proportional hazard methods.
resultsA total of 2,205 mCRPC patients were included in this study. Low ALB independently predicted the OS in both cohorts (HR, 1.54; 95%CI, 1.34-1.78 and HR, 1.40; 95%CI, 1.21-1.64, respectively), while low BMI independently predicted the OS only in the post-chemotherapy cohort (HR, 1.30; 95%CI, 1.12-1.50) but not in the pre-chemotherapy cohort (HR, 1.19; 95%CI, 0.98-1.43). By combining BMI (<25 kg/m
conclusionsOur results demonstrate that the combination of BMI and ALB better characterizes the risk groups irrespective of previous chemotherapy. Patients with high BMI but low ALB have higher risk of death than patients with low BMI but high ALB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.